Saphenous vein graft interventions

Emmanouil S. Brilakis, Michael Lee, Julinda Mehilli, Konstantinos Marmagkiolis, Josep Rodes-Cabau, Rajesh Sachdeva, Anna Kotsia, George Christopoulos, Bavana V. Rangan, Atif Mohammed, Subhash Banerjee

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Saphenous vein graft (SVG) percutaneous coronary intervention (PCI) currently accounts for approximately 6% of all PCIs and is associated with increased risk for distal embolization and subsequent SVG failure compared with native coronary artery PCI. To minimize the risk for distal embolization, embolic protection devices should be used during SVG PCI when technically feasible. To minimize the risk for in-stent restenosis and the need for repeat PCI, drug eluting stents should be utilized in patients without contraindications to long-term antiplatelet therapy. Treating native coronary artery lesions is preferable to SVG PCI when technically feasible.

Original languageEnglish (US)
Article number301
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume16
Issue number5
DOIs
StatePublished - May 2014

    Fingerprint

Keywords

  • Drug eluting stent
  • Internal mammary artery
  • Outcomes
  • Percutaneous coronary intervention
  • Saphenous vein grafts

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Brilakis, E. S., Lee, M., Mehilli, J., Marmagkiolis, K., Rodes-Cabau, J., Sachdeva, R., Kotsia, A., Christopoulos, G., Rangan, B. V., Mohammed, A., & Banerjee, S. (2014). Saphenous vein graft interventions. Current Treatment Options in Cardiovascular Medicine, 16(5), [301]. https://doi.org/10.1007/s11936-014-0301-x